SCHEMBL16709595

SCHEMBL16709595

COCCNC(=O)Nc1ccc(N)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ATM Q13315 1/20 0.48
MAPT P10636 2/20 0.44
RAB9A P51151 2/20 0.43
GAA P10253 2/20 0.43
MAPK1 P28482 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
CMA1 P23946 1/20 0.42
PTGER4 P35408 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
EPHX2 P34913 1/20 0.41
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16709591 0.80 HTT (0.58) LMNAMEN1KMT2AATMMAPT
SCHEMBL3006202 0.76 HPGD (0.51) LMNAMAPTRAB9AGAAMAPK1
SCHEMBL8216849 0.74 ATM (0.40) MEN1KMT2AATMMAPK1ALDH1A1
SCHEMBL11791826 0.74 PTGER4 (0.55) LMNAMAPTRAB9AGAAMAPK1
SCHEMBL11643938 0.74 CYP1A2 (0.54) LMNAMEN1KMT2AMAPK1HPGD
SCHEMBL30725839 0.73 CA1 (0.61) MAPTRAB9AGAAMAPK1ALDH1A1
SCHEMBL116618 0.73 CA1 (0.61) MAPTRAB9AGAAMAPK1ALDH1A1
SCHEMBL11647163 0.73 PTGER4 (0.45) LMNAMEN1KMT2AGAAMAPK1
SCHEMBL4788372 0.72 LMNA (0.44) LMNAMEN1KMT2AATMALDH1A1
SCHEMBL11641270 0.72 NPC1 (0.51) MEN1KMT2AMAPTGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9751843-B2 Substituted uracils and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-05 US disclosed
US-9751843-B2 Substituted uracils and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-05 US disclosed
US-20160297771-A1 SUBSTITUTED URACILS AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-13 US disclosed
US-20160297771-A1 SUBSTITUTED URACILS AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-13 US disclosed
CN-105980381-A Substituted uracils and use thereof 拜耳医药股份有限公司 2016-09-28 CN disclosed
WO-2015067630-A1 SUBSTITUTED URACILS AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297771-A1 SUBSTITUTED URACILS AND USE THEREOF UNG, UMPS, TYMP LMNA 3261/4885MEN1 2815/4885KMT2A 3207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.